Brief: Vertex Receives CHMP Positive Opinion For Casgevy

Crispr Therapeutics AG

15/12/2023 13:33

Dec 15 (Reuters) - Vertex Pharmaceuticals Inc  VRTX.O :
    * VERTEX RECEIVES CHMP POSITIVE OPINION FOR THE FIRST CRISPR/CAS9
GENE-EDITED
THERAPY, CASGEVY™ (EXAGAMGLOGENE AUTOTEMCEL), FOR THE TREATMENT OF SICKLE CELL
DISEASE AND TRANSFUSION-DEPENDENT BETA THALASSEMIA
    * VERTEX PHARMACEUTICALS INC: APPROVAL DECISION FROM EUROPEAN COMMISSION IS
EXPECTED IN Q1 2024

Source text for Eikon:  ID:nBw7GGTFda 
Further company coverage:  VRTX.O 

 ((Reuters.Briefs@thomsonreuters.com;;))